Psychiatria polska最新文献_第4页

Mitigation of mephedrone craving with bupropion in a HIV-positive male who has sex with men - a case report. 安非他酮缓解男男性行为者艾滋病病毒阳性男性对甲氧麻黄酮的渴望-一个病例报告。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/202518

Przemysław Łukasiewicz

{"title":"Mitigation of mephedrone craving with bupropion in a HIV-positive male who has sex with men - a case report.","authors":"Przemysław Łukasiewicz","doi":"10.12740/PP/202518","DOIUrl":"https://doi.org/10.12740/PP/202518","url":null,"abstract":"Chemsex, defined as the use of psychoactive substances to sustain sexual activity or intensify the experiences associated with it, occurs primarily among men who have sex with men. This article presents the case of a 30-year-old HIV-positive man who engaged in chemsex primarily with mephedrone and, occasionally, GHB, and who subsequently developed mephedrone dependence. He sought psychiatric care because of severe drug craving, recurrent depressive and anxiety symptoms accompanying withdrawal syndromes, and fears of losing control over his addiction. A comprehensive evaluation revealed no co-occurring psychiatric disorders or other clinically significant medical abnormalities apart from known HIV infection, which was effectively controlled with antiretroviral therapy. After initiation of bupropion at a dose of 150 mg per day, improvement in mood, reduction in mephedrone craving, and a marked decrease in the frequency of chemsex were observed. This supports the hypothesis that bupropion-induced stabilization of dopaminergic and noradrenergic neurotransmission may indirectly attenuate craving for stimulants such as mephedrone. Psychotherapy introduced during the course of treatment further supported the patient in pursuing long-term abstinence. To our knowledge, this is the first case report describing successful reduction of drug craving with bupropion in an HIV-positive patient engaging in chemsex without co-occurring psychiatric disorders. This case suggests the potential utility of bupropion in reducing mephedrone craving in individuals engaging in chemsex; however, conclusions drawn from a single clinical observation should be interpreted with caution.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":"60 2","pages":"207-212"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolutionary aspects of schizophrenia. 精神分裂症的进化方面。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/202864

Paweł Wójciak, Filip Rybakowski

{"title":"Evolutionary aspects of schizophrenia.","authors":"Paweł Wójciak, Filip Rybakowski","doi":"10.12740/PP/202864","DOIUrl":"https://doi.org/10.12740/PP/202864","url":null,"abstract":"Disorders of the mental life have accompanied the species Homo sapiens since the beginning of its existence. One of the most serious is schizophrenia. Its presence in all cultures, with similar frequency, indicates that this disease probably appeared before the formation of the oldest genetically isolated populations. Schizophrenia is also associated with the phenomenon of the so-called \"evolutionary paradox\". It concerns a situation in which genetic variants predisposing to the disease persist in the population despite the deterioration of the fitness of people affected by the disease, early onset of the disease, higher mortality and, consequently, reduced reproductive capacity. This seemingly contradicts the classical Darwinian theory of evolution, according to which natural selection promotes genetic variants that give an advantage in the above areas. In this article, we will try to present theories and hypotheses, often complementary, sometimes contradictory, that try to explain the causes of this puzzle. We will look at the evidence that allows us to treat schizophrenia as an adaptive advantage, but also that which considers it an unfavorable, although inevitable, product of brain evolution. We will point to potential genetic, metabolic, and social factors that may be involved in perpetuating the \"evolutionary paradox\" of schizophrenia mentioned above.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":"60 2","pages":"171-190"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI in schizophrenia treatment: personalizing therapy and predicting relapses. 人工智能在精神分裂症治疗中的应用：个性化治疗和预测复发。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/203944

Jan Barański

{"title":"AI in schizophrenia treatment: personalizing therapy and predicting relapses.","authors":"Jan Barański","doi":"10.12740/PP/203944","DOIUrl":"https://doi.org/10.12740/PP/203944","url":null,"abstract":"The objective of this study is to present the potential of Artificial Intelligence (AI) in the treatment of schizophrenia, with a particular focus on therapy personalization and relapse prediction. The significance of schizophrenia as a major health issue and the associated therapeutic challenges, such as the low effectiveness of traditional treatment methods and difficulties in patient adherence to recommendations, are discussed. The study analyzes the application of AI in processing large datasets, including biometric, behavioral, and genetic information, which support the individualization of therapy. Examples of AI-driven projects are presented, such as patient language analysis for early relapse detection and real-time health monitoring devices. It is highlighted that such solutions can improve treatment effectiveness and reduce hospitalization rates. Special attention is given to predictive algorithms based on machine learning that enable the identification of schizophrenia relapses through complex data patterns. The study also emphasizes the integration of AI with VR (Virtual Reality) and AR (Augmented Reality) technologies, which can help patients manage their symptoms more effectively. The paper concludes with reflections on the future of AI in psychiatry, pointing to its potential to improve the accessibility and quality of healthcare, particularly in resource-limited regions.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":"60 2","pages":"191-205"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Muscle Dysmorphic Disorder Inventory (MDDI) - Polish adaptation, women's version. 肌肉畸形障碍量表(MDDI) -波兰改编，女性版。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/OnlineFirst/202230

Beata Ziółkowska, Dorota Łoboda, Żaneta Żaczek

{"title":"Muscle Dysmorphic Disorder Inventory (MDDI) - Polish adaptation, women's version.","authors":"Beata Ziółkowska, Dorota Łoboda, Żaneta Żaczek","doi":"10.12740/PP/OnlineFirst/202230","DOIUrl":"10.12740/PP/OnlineFirst/202230","url":null,"abstract":"Objectives: Muscle dysmorphia is a disorder in which one incorrectly assesses one's body as too thin and insufficiently muscular. Data on dysmorphia in the female population are still limited. The aim of the study was to culturally adapt and validate the Muscle Dysmorphic Disorder Inventory (MDDI) by Hildebrandt et al. (2004) in the female population.Methods: The study included 204 women aged 18 to 35 years. In addition to the MDDI, the following were used: (1) a personal questionnaire to control secondary variables (e.g. BMI, sexual orientation, self-rated health), (2) the Body Image Questionnaire (BIQ) to check the validity of the validated tool, and (3) a subscale of the KOMPAN questionnaire to operationalise the variable \"physical activity\".Results: It was noted that there are intergroup differences in the intensity of muscle dysmorphia symptoms in the studied sample between women involved in moderate and high levels of leisure-time physical activity. It was proven that the higher the BMI value and the greater the difference between actual and expected body weight, the greater the intensity of muscle dysmorphia symptoms in the studied women.Conclusions: The results of the study confirmed the three-factor structure of the MDDI-PL and demonstrated its satisfactory reliability both as a whole and in its separate subscales. MDDI-PL can be used as a screening tool, especially for examining women who engage in physical activity (including competitively).","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":" ","pages":"323-338"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ketamine - mechanisms of action as an antidepressant. 氯胺酮——抗抑郁药的作用机制。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/OnlineFirst/202128

Bronisław Gębik, Katarzyna Bliźniewska-Kowalska, Piotr Gałecki

{"title":"Ketamine - mechanisms of action as an antidepressant.","authors":"Bronisław Gębik, Katarzyna Bliźniewska-Kowalska, Piotr Gałecki","doi":"10.12740/PP/OnlineFirst/202128","DOIUrl":"10.12740/PP/OnlineFirst/202128","url":null,"abstract":"Since the year 2000, ketamine and its enantiomers have been studied for their antidepressant effects. This paper will briefly summarise the journey of ketamine from an anaesthetic to an antidepressant. The text will present the key mechanisms of its action, as well as the actions of its metabolites. The aim of this article is to describe the role of specific groups of receptors in activation of important metabolic pathways and in production of factors such as mammalian target of rapamycin kinase (mTOR) and brain-derived neurotrophic factor (BDNF), in order to comprehensively present a potential link between ketamine, ketamine's enantiomers and its metabolites with terms such as neuroplasticity and antidepressant action. Another important part of this article is a summary of arguments for and against importance of specific mechanisms of ketamine action and to compare (S) and (R)-ketamine's potential to act as an antidepressant. This article may be particularly helpful for researchers in determining further research directions and serve as a summary of the current state of knowledge regarding the mechanisms of ketamine's action and the latest therapeutic possibilities in the treatment of affective disorders.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":" ","pages":"225-243"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional Capacity in Older Adults with Depressive Disorders. 老年抑郁症患者的功能能力。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/200629

Wojciech Datka, Wojciech Mateusz Rachel, Szymon Krupnik, Marek Żak, Rafał R Jaeschke, Dominika Dudek

{"title":"Functional Capacity in Older Adults with Depressive Disorders.","authors":"Wojciech Datka, Wojciech Mateusz Rachel, Szymon Krupnik, Marek Żak, Rafał R Jaeschke, Dominika Dudek","doi":"10.12740/PP/200629","DOIUrl":"https://doi.org/10.12740/PP/200629","url":null,"abstract":"Objectives: The authors evaluated functional capacity, including locomotion and motor skills, in individuals over 60 years old diagnosed with major depressive disorder (MDD) and analyzed the impact of regular physical activity on mood and cognitive functions.Methods: This cross-sectional study involved 71 patients (mean age: 71 ± 8 years) with mild or moderate depressive episodes, assessed using the Geriatric Depression Scale (GDS). Participants scoring <24 points on the Mini-Mental State Examination (MMSE) were excluded. The authors evaluated physical capacity using the following tests: Timed Up and Go (TUG), Single Leg Stance (SLS) with open or closed eyes (SLS OP/CL), and the 30-Second Chair Stand Test (30sCST). The results were compared with population norms, and the relationship between the severity of depressive symptoms and physical capacity was analyzed using Spearman's rank correlation coefficient.Results: Significant reductions in physical capacity were observed in the study group. Test results indicate a significant negative correlation between the severity of depressive symptoms and functional capacity, particularly for SLS OP (r = -0.33; p = 0.042) and 30sCST (r = -0.26; p = 0.031). Women scored worse than men, and a higher body mass index (BMI) correlated with reduced physical capacity.Conclusions: The findings indicate a significant impact of depression on the deterioration of functional capacity in older adults, emphasizing the importance of incorporating physical interventions into the treatment of this population.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":"60 2","pages":"213-223"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stigmatization of mentally ill people - a contemporary problem. 对精神病患者的污名化——一个当代问题。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/199770

Jakub Gdowski, Krzysztof Szczygieł, Piotr Podwalski, Jerzy Samochowiec

{"title":"Stigmatization of mentally ill people - a contemporary problem.","authors":"Jakub Gdowski, Krzysztof Szczygieł, Piotr Podwalski, Jerzy Samochowiec","doi":"10.12740/PP/199770","DOIUrl":"https://doi.org/10.12740/PP/199770","url":null,"abstract":"Stigmatization and discrimination of people due to their specific characteristics is a widespread problem, both in Poland and worldwide. Stigmatization of people with mental disorders and diseases is a particular type of it. Although this phenomenon has its roots in Antiquity and the Middle Ages, and was scientifically described several dozen years ago, it is still a current and unsolved problem. Stigmatization can take place on different levels and appear as autostigmatization, community-related stigmatization, and institutional stigmatization. It takes different forms and has varying negative effects. Counteracting this situation and eliminating its effects, that have already arisen, is a vital necessity and an essential activity of the society in order to provide better functioning and treatment for people with mental illness. Challenges in this area are faced both by state institutions responsible for the health care system and by private entities such as NGOs, media corporations, and companies employing people. The individual commitment of each and every person is also important to prevent and respond appropriately to the stigmatization of people affected by mental illness.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":"60 2","pages":"245-258"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Depressive and anxiety symptoms in patients with celiac disease - co-occurrence and mutual dependencies. 乳糜泻患者的抑郁和焦虑症状-共现和相互依赖

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/OnlineFirst/203065

Karolina Patrycja Sas, Damian Zieliński, Magdalena Piegza

{"title":"Depressive and anxiety symptoms in patients with celiac disease - co-occurrence and mutual dependencies.","authors":"Karolina Patrycja Sas, Damian Zieliński, Magdalena Piegza","doi":"10.12740/PP/OnlineFirst/203065","DOIUrl":"10.12740/PP/OnlineFirst/203065","url":null,"abstract":"It is estimated that approximately 1% to 3% of people in the world suffer from celiac disease, which mainly affects Caucasians. The HLA-DQ2 and HLA-DQ8 haplotypes present in the majority of the European population diagnosed with celiac disease are helpful in diagnosing the disease. The main symptom is chronic inflammation of the small intestine and atrophy of the intestinal villi, but neurological and psychopathological symptoms, such as depression or severe anxiety, may also occur. Numerous studies show that a gluten-free diet alleviates the psychological symptoms associated with celiac disease. However, strict dietary requirements often constitute a challenge for patients, changing their current lifestyle and limiting its comfort. In patients with celiac disease, increased symptoms of depression and anxiety are observed, and the duration of the disease affects the severity of the above symptoms. Currently, therapeutic benefits are attributed especially to a gluten-free diet, but recent scientific reports indicate a comparable clinical effect in patients using probiotics. The course of the disease is also influenced by the emotional support of the patient's family, causing a milder course of the disease. Caregivers of patients should pay special attention to the symptoms of anxiety and depression in their patients, because they are often unnoticed, which leads to an unfavourable course of the disease.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":" ","pages":"293-307"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145638153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of depressive symptoms between patients with myeloproliferative neoplasms without the Philadelphia chromosome treated with interferon alpha and patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. 无费城染色体骨髓增殖性肿瘤患者用干扰素治疗与慢性骨髓性白血病患者用酪氨酸激酶抑制剂治疗抑郁症状的比较

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/OnlineFirst/202763

Katarzyna Gibek, Tomasz Sacha

{"title":"Comparison of depressive symptoms between patients with myeloproliferative neoplasms without the Philadelphia chromosome treated with interferon alpha and patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.","authors":"Katarzyna Gibek, Tomasz Sacha","doi":"10.12740/PP/OnlineFirst/202763","DOIUrl":"10.12740/PP/OnlineFirst/202763","url":null,"abstract":"Objectives: The aim of the study was to compare the occurrence of depressive symptoms between a group of patients with MPN (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) treated with interferon-alpha and patients with chronic myelogenous leukaemia (CML) treated with tyrosine kinase inhibitors and to check whether individual side effects may contribute to the occurrence of depressive symptoms.Methods: The study involved 175 adult patients with MPN and CML who had been treated with IFNα or TKI for a minimum of 3 months. The study used: the David Goldberg Questionnaire (GHQ-28), the Four-Dimensional Questionnaire 4DSQ and our own survey.Results: Approximately 40% of patients with MPN and almost 20% of patients with CML obtained a moderately and strongly elevated score on the depression scale. The analysis revealed no statistically significant differences between women and men. Bone and joint pain (β=0.196, p=0.013), nausea and indigestion (β=0.191, p=0.007), fatigue (β=0.136, p=0.053), cramps and muscle aches (β=0.159, p=0.038) and diarrhoea (β=0.138, p=0.050) were side effects that affected the possibility of developing depressive symptoms in both groups. The common predictor of depressive symptoms was the number of side effects, the type of illness, and age. The older the person was, the greater the severity of depressive symptoms.Conclusions: There are significant differences in the prevalence of depression between patients with CML and MPN. Specific side effects of interferon-alpha and TKI treatment influence the occurrence of depressive symptoms. No association between interferon treatment and the development of depression was confirmed.","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":" ","pages":"259-274"},"PeriodicalIF":1.5,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial. 社论。

IF 1.5 4区医学

Psychiatria polska Pub Date : 2026-04-30 DOI: 10.12740/PP/222709

Dominika Dudek, Jerzy A Sobański, Katarzyna Klasa

引用次数: 0